Monte Rosa Therapeutics, Inc. GLUE Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s net change in cash?
- Monte Rosa Therapeutics, Inc. (GLUE) reported net change in cash of $29.97M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s net change in cash changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s net change in cash increased by 120.6% year-over-year, from -$145.71M to $29.97M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s net change in cash?
- Over 2 years (2021 to 2023), Monte Rosa Therapeutics, Inc.'s net change in cash has grown at a -52.8% compound annual growth rate (CAGR), from $325.9M to $72.49M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.